Cargando…

Relationship and factors responsible for regulating fasting and post-challenge plasma glucose levels in the early stage development of type 2 diabetes mellitus

AIMS/INTRODUCTION: Elevation of 2-h plasma glucose (2-h PG) levels keeps step with fasting plasma glucose (FPG) levels elevation, but some individuals show dominant elevation of 2-h PG and others FPG. We analyzed dependent and independent relationships between 2-h PG and FPG, and investigated the fa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aoyama-Sasabe, Sae, Xin, Xin, Taniguchi, Ataru, Nakai, Yoshikatsu, Mitsui, Rie, Tsuji, Hideaki, Yabe, Daisuke, Yasuda, Koichiro, Kurose, Takeshi, Inagaki, Nobuya, Seino, Yutaka, Fukushima, Mitsuo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2014
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4234229/ https://www.ncbi.nlm.nih.gov/pubmed/25422766 http://dx.doi.org/10.1111/jdi.12239

Ejemplares similares

Insulin Secretory Defect and Insulin Resistance in Isolated Impaired Fasting Glucose and Isolated Impaired Glucose Tolerance
por: Aoyama-Sasabe, Sae, et al.
Publicado: (2016)

Insulin secretory capacity and insulin sensitivity in impaired fasting glucose in Japanese
por: Mitsui, Rie, et al.
Publicado: (2012)

Smoking, white blood cell counts, and TNF system activity in Japanese male subjects with normal glucose tolerance
por: Watanabe, Naoya, et al.
Publicado: (2011)

GIP and GLP‐1, the two incretin hormones: Similarities and differences
por: Seino, Yutaka, et al.
Publicado: (2010)

β Cell Dysfunction Versus Insulin Resistance in the Pathogenesis of Type 2 Diabetes in East Asians
por: Yabe, Daisuke, et al.
Publicado: (2015)

Smoking and adipose tissue inflammation suppress leptin expression in Japanese obese males: potential mechanism of resistance to weight loss among Japanese obese smokers
por: Nagayasu, Shintaro, et al.
Publicado: (2012)

Circadian rhythms and diabetes
por: Kurose, Takeshi, et al.
Publicado: (2011)

Little enhancement of meal‐induced glucagon‐like peptide 1 secretion in Japanese: Comparison of type 2 diabetes patients and healthy controls
por: Yabe, Daisuke, et al.
Publicado: (2010)

Is caloric restriction enough to increase longevity? Fasting and circadian alignment
por: Hamamoto, Yoshiyuki, et al.
Publicado: (2023)

Lipopolysaccharide inhibits hepatic gluconeogenesis in rats: The role of immune cells
por: Tanaka, Hiroshi, et al.
Publicado: (2017)

Factors influencing the durability of the glucose‐lowering effect of sitagliptin combined with a sulfonylurea
por: Kubota, Akira, et al.
Publicado: (2014)

Drug-Induced Generalized Skin Eruption in a Diabetes Mellitus Patient Receiving a Dipeptidyl Peptidase-4 Inhibitor Plus Metformin
por: Nakatani, Kaori, et al.
Publicado: (2012)

Bullous pemphigoid with dipeptidyl peptidase‐4 inhibitors: Clinical features and pathophysiology
por: Murakami, Takaaki, et al.
Publicado: (2019)

Unmet needs in current clinical practice for insulinoma: Lessons from nationwide studies in Japan
por: Murakami, Takaaki, et al.
Publicado: (2021)

Comparison of incretin immunoassays with or without plasma extraction: Incretin secretion in Japanese patients with type 2 diabetes
por: Yabe, Daisuke, et al.
Publicado: (2011)

Incretin concept revised: The origin of the insulinotropic function of glucagon‐like peptide‐1 – the gut, the islets or both?
por: Yabe, Daisuke, et al.
Publicado: (2017)

Liraglutide in Adults with Type 2 Diabetes: Global Perspective on Safety, Efficacy and Patient Preference
por: Yabe, Daisuke, et al.
Publicado: (2011)

Dipeptidyl peptidase‐4 inhibitors and sulfonylureas for type 2 diabetes: Friend or foe?
por: Yabe, Daisuke, et al.
Publicado: (2014)

Dipeptidyl peptidase‐4 inhibitors and prevention of bone fractures: Effects beyond glyemic control
por: Yabe, Daisuke, et al.
Publicado: (2012)

Glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1: Incretin actions beyond the pancreas
por: Seino, Yutaka, et al.
Publicado: (2013)

Cardiovascular safety trials of incretin‐based drugs: What do they mean?
por: Yabe, Daisuke, et al.
Publicado: (2016)

Effects of DPP‐4 inhibitor linagliptin and GLP‐1 receptor agonist liraglutide on physiological response to hypoglycaemia in Japanese subjects with type 2 diabetes: A randomized, open‐label, 2‐arm parallel comparative, exploratory trial
por: Yabe, Daisuke, et al.
Publicado: (2016)

Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes patients: The association between remaining β‐cell function and the achievement of the glycated hemoglobin target 1 year after initiation
por: Usui, Ryota, et al.
Publicado: (2017)

Reply to the comment of Wilbrink et al. on Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes: The association between remaining β‐cell function and the achievement of the HbA1c target 1 year after initiation
por: Usui, Ryota, et al.
Publicado: (2018)

Relationship between deterioration of glycated hemoglobin‐lowering effects in dipeptidyl peptidase‐4 inhibitor monotherapy and dietary habits: Retrospective analysis of Japanese individuals with type 2 diabetes
por: Kuwata, Hitoshi, et al.
Publicado: (2017)

Current understanding of imeglimin action on pancreatic β‐cells: Involvement of mitochondria and endoplasmic reticulum homeostasis
por: Fauzi, Muhammad, et al.
Publicado: (2022)

Incretin‐based drugs for type 2 diabetes: Focus on East Asian perspectives
por: Seino, Yutaka, et al.
Publicado: (2016)

The journey to understanding incretin systems: Theory, practice and more theory
por: Yabe, Daisuke, et al.
Publicado: (2019)

Twincretin as a potential therapeutic for the management of type 2 diabetes with obesity
por: Usui, Ryota, et al.
Publicado: (2019)

The Asian Association for the Study of Diabetes: The first 10 years and the next 10 years
por: Seino, Yutaka, et al.
Publicado: (2020)

Meal sequence and glucose excursion, gastric emptying and incretin secretion in type 2 diabetes: a randomised, controlled crossover, exploratory trial
por: Kuwata, Hitoshi, et al.
Publicado: (2015)

Ceritinib‐associated hyperglycemia in the Japanese Adverse Drug Event Report Database
por: Fujita, Haruka, et al.
Publicado: (2019)

Sodium‐glucose co‐transporter‐2 inhibitor use and dietary carbohydrate intake in Japanese individuals with type 2 diabetes: A randomized, open‐label, 3‐arm parallel comparative, exploratory study
por: Yabe, Daisuke, et al.
Publicado: (2017)

Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A subgroup analysis by baseline variables in the PIONEER 9 and PIONEER 10 trials
por: Yabe, Daisuke, et al.
Publicado: (2022)

Solid‐phase extraction treatment is required for measurement of active glucagon‐like peptide‐1 by enzyme‐linked immunosorbent assay kit affected by heterophilic antibodies
por: Hasegawa, Tomonori, et al.
Publicado: (2018)

Beta‐cell replacement strategies for diabetes
por: Kieffer, Timothy J, et al.
Publicado: (2017)

Bullous pemphigoid associated with dipeptidyl peptidase‐4 inhibitors: A report of five cases
por: Yoshiji, Satoshi, et al.
Publicado: (2017)

Association of glucagon‐like peptide‐1 receptor‐targeted imaging probe with in vivo glucagon‐like peptide‐1 receptor agonist glucose‐lowering effects
por: Murakami, Takaaki, et al.
Publicado: (2020)

Evaluation of large‐scale clinical trials on cardiovascular disease risk in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase 4 inhibitors and a new class of drugs
por: Kurose, Takeshi, et al.
Publicado: (2017)

Sorting nexin 19 regulates the number of dense core vesicles in pancreatic β‐cells
por: Harashima, Shin‐ichi, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_2ejq0s9u83k8t32qu9pesqbfvu